Table 6.
Food and drug administration indications of immunosuppressive agents
| Generic | Brand | FDA indication | Company |
| Basiliximab | Simulect | Prevention of acute rejection in kidney transplantatation | Novartis |
| Rabbit anti-thymocyte globulin | Thymoglobulin | Treatment of corticosteroid resistant rejection in kidney transplantation | Genzyme |
| Alemtuzumab | Campath | Treatment of B-cell chronic lymphocytic leukemia | Berlex Laboratories |
| Efaluzimab | No longer FDA approved Raptiva | Management of moderate to severe chronic plaque psoriasis in adults | Genentech-Merck |
| Alefacept | Amevive | Treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy | Astellas |
| Tacrolimus prolonged release | Advagraf (in Canada) | Not FDA approved | Astellas |
| Cyclosporine | Neoral | Prevention of acute rejection in renal transplant recipients | Novartis |
| Tacrolimus | Prograf | Prevention of acute rejection in renal transplant recipients | Astellas |
| Voclosporin | Not FDA approved | Isotechnika Pharma | |
| Everolimus | Afinitor, Zortress | Treatment of advanced renal cell cancer (Afinitor®); treatment of subependymal giant cell astrocytom associated with tuberous sclerosis (Afinitor®); treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (Afinitor®); prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants (Zortress) | Novartis |
| Azathioprine | Imuran | Adjunctive therapy in prevention of rejection of kidney transplants; management of active rheumatoid arthritis | Glaxo-Smith-Kline |
| MMF | Cellcept | Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal cardiac, or hepatic transplants | Genentech |
| Mycophenolate sodium | Myfortic | Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal transplantation | Novartis |
| Mizoribine | Not FDA approved | Asahi Kasei Pharma | |
| Sotrastaurin, AEB-071 | Not FDA approved | Novartis | |
| Belatacept, BMS224818 | Nulojix | Prevention of acute rejection in renal transplant recipients | Bristol-Myers-Squibb |
| Tolfacitinib, formerly tasocitinib, CP-690550 | Not FDA approved | Pfizer | |
| Rituximab | Rituxan | Treatment of CD20-positive non-Hodgkin’s lymphomas; Treatment of moderately- to severely-active rheumatoid arthritis in adult patients with inadequate response to one or more TNF antagonists; Treatment of Wegener’s granulomatosis; Treatment of microscopic polyangiitis | Genentech |
| Bortezomib | Velcade | Treatment of multiple myeloma; treatment of relapsed or refractory mantle cell lymphoma | Millenium Pharmaceuticals |
| Eculizumab | Soliris | Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis | Alexion Pharmaceuticals |
FDA: Food and drug administration.